COMMUNIQUÉS West-GlobeNewswire

DLH to Announce Fiscal 2025 Third Quarter Financial Results
28/07/2025
ATLANTA, July 28, 2025 (GLOBE NEWSWIRE) -- DLH Holdings Corp. (NASDAQ: DLHC) (“DLH” or the “Company”), a leading provider of science research and development, systems engineering and integration, and digital [...]
New Publication in Expert Review of Anti-infective Therapy Evaluates Brincidofovir as Potential Antiviral Treatment for Mpox
28/07/2025
Ongoing mpox outbreak continues to be a global health threat and is driving need for greater therapeutic research and innovation GAITHERSBURG, Md., July 28, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS [...]
Emergent Applauds Availability of Over-the-Counter Naloxone in U.S. House of Representatives
28/07/2025
GAITHERSBURG, Md., July 28, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announces its recognition of the U.S. House of Representatives for adding over-the-counter (OTC) naloxone to every AED [...]
Aclaris Therapeutics Announces Leadership Transition
28/07/2025
- Roland Kolbeck, Ph.D. Appointed as Chief Scientific Officer - - Joe Monahan, Ph.D. will Continue to Support Aclaris as Special Scientific Advisor to the Chief Executive Officer through March 2026 as Part of Planned [...]
Enlivex Reaffirms August 18, 2025 As Target Date For Announcement of Phase II Topline Data
28/07/2025
Nes-Ziona, Israel, July 28, 2025 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company, today announced that all 134 patients in its [...]
FibroBiologics Files Patent for Methods of Generating Multipotent Cells from Donor Tissue for Clinical Applications
28/07/2025
HOUSTON, July 28, 2025 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 275+ patents issued and pending with a focus on the development of [...]
Fifty 1 Labs, Inc. to Host Virtual Shareholder Teleconference Featuring World-Class Leadership Team, including Dr. James Orbinski, who received the Nobel Peace Prize on Behalf of Médecins Sans Frontières
28/07/2025
SEATTLE, July 28, 2025 (GLOBE NEWSWIRE) -- Fifty 1 Labs, Inc. ( OTC: FITY ), a leader in AI-powered health and wellness solutions, today announced it will host a virtual shareholder teleconference on Monday, July 28, [...]
Supernus Pharmaceuticals Announces Expiration of Hart-Scott-Rodino Waiting Period for Sage Therapeutics, Inc. Tender Offer
28/07/2025
ROCKVILLE, Md., July 28, 2025 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc., a Delaware corporation (NASDAQ: SUPN) (" Supernus ", and the "Company"), today announced that the required waiting period under the Hart- [...]
NKGen Biotech Presents Troculeucel Mechanism of Action with Corresponding Phase 1 Biomarker Data at the Alzheimer’s Association International Conference 2025
28/07/2025
Troculeucel, a cryopreserved autologous, non-genetically modified NK cell product, appears to cross the blood brain barrier (BBB) via CXCR3, to reduce neuroinflammation via a simple IV administration. Troculeucel was [...]
IMUNON Announces Stock Dividend Boosting Shareholder Value
28/07/2025
Stock Dividend Reflects Company’s Confidence in its Phase 3 Study, Long-term Growth Potential, and Dedication to Shareholders LAWRENCEVILLE, N.J., July 28, 2025 (GLOBE NEWSWIRE) -- IMUNON , Inc. (Nasdaq: IMNN) , a [...]
Alzamend Neuro to Present at the 2025 Military Health System Research Symposium
28/07/2025
Session Topic is the I nnovation and Current Directions in Military Suicide Prevention, Research, and Programs Presentation Title is Quantitate Differences in Lithium Brain-to-Plasma Exposure in PTSD Subjects Between [...]
ProQR Announces Upcoming Presentation at RNA Editing Summit
28/07/2025
LEIDEN, Netherlands & CAMBRIDGE, Mass., July 28, 2025 (GLOBE NEWSWIRE) -- ProQR Therapeutics NV (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies based on its [...]
Phathom Pharmaceuticals to Report Second Quarter 2025 Financial Results and Provide Business Update on Thursday, August 7, 2025
28/07/2025
Management to host conference call on Thursday, August 7, 2025, at 8:00 am EDT FLORHAM PARK, N.J., July 28, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on [...]
Hyperion DeFi Purchases Additional $5 Million in HYPE for Kinetiq iHYPE Strategy
28/07/2025
Increases total holdings to 1,535,772 HYPE Company to host investor webinar on Tuesday, July 29 th at 2:00pm ET LAGUNA HILLS, Calif., July 28, 2025 (GLOBE NEWSWIRE) -- Hyperion DeFi, Inc. (NASDAQ: HYPD) (“Hyperion DeFi [...]
NetraMark Signs Contract with AlgoTx to Enhance Clinical Trial Design for ATX01
28/07/2025
TORONTO, July 28, 2025 (GLOBE NEWSWIRE) -- NetraMark Holdings Inc. (the “Company” or “NetraMark”) (CSE: AIAI) (OTCQB: AINMF) (Frankfurt: PF0) a premier artificial intelligence (AI) company transforming clinical trials [...]
Legend Biotech to Host Investor Conference Call on Second Quarter 2025 Results
28/07/2025
SOMERSET, N.J., July 28, 2025 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, will host a conference call for investors at 8:00 am ET on Monday, August 11 [...]
Acumen Pharmaceuticals Presents Studies Showing the Utility of a pTau217 Assay in Screening for a Phase 2 Alzheimer’s Disease Trial and Validates Sabirnetug Oligomer-Selectivity, at the Alzheimer’s Association International Conference (AAIC) 2025
28/07/2025
NEWTON, Mass., July 28, 2025 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets soluble amyloid beta oligomers (AβOs) [...]
UroGen Announces Publication of Phase 3b Study Results Demonstrating the Feasibility of Home Instillation of ZUSDURI™ for Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer in Reviews in Urology
28/07/2025
PRINCETON, N.J., July 28, 2025 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative treatments for urothelial and specialty cancers, today [...]
Soleno Therapeutics to Report Second Quarter 2025 Financial Results on August 6, 2025, at 4:30 PM ET
28/07/2025
REDWOOD CITY, Calif., July 28, 2025 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced [...]

Pages